MCID: WLM013
MIFTS: 69

Wilms Tumor 1

Categories: Genetic diseases, Rare diseases, Cancer diseases, Fetal diseases, Nephrological diseases

Aliases & Classifications for Wilms Tumor 1

MalaCards integrated aliases for Wilms Tumor 1:

Name: Wilms Tumor 1 53 71 28
Nephroblastoma 53 12 49 55 28 14 69
Wilms' Tumor 12 72 49
Wilms Tumor 53 55 41
Wt1 53 49 71
Bilateral Wilms Tumor 49 69
Renal Wilms' Tumor 12 14
Nonanaplastic Renal Wilm's Tumor 12
Nonanaplastic Kidney Wilms Tumor 69
Nonanaplastic Renal Wilms Tumor 12
Childhood Renal Wilms' Cancer 12
Childhood Kidney Wilms Tumor 69
Childhood Renal Wilms Tumor 12
Adult Renal Wilms' Tumor 12
Adult Kidney Wilms Tumor 69
Renal Embryonic Tumor 55
Wilms Tumor, Somatic 53
Adult Nephroblastoma 12
Wilms Tumor, Type 1 53
Renal Wilms Tumor 12
Wilms Tumor-1 13

Characteristics:

Orphanet epidemiological data:

55
nephroblastoma
Inheritance: Autosomal dominant,Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe),1-9/1000000 (United Kingdom),1-5/10000 (Europe); Age of onset: Childhood; Age of death: any age;

OMIM:

53
Inheritance:
autosomal dominant
somatic mutation

Miscellaneous:
genetic heterogeneity
majority of wilms tumors are sporadic
onset between 2-5 years
rare adult cases reported
5-10% of all wilms tumor are bilateral
21% of hereditary wilms tumor are bilateral
associated with several congenital malformation syndromes (wagr , abnormal urogenital development syndromes)
two-step mutation hypothesis (germline mutation followed by somatic mutation or two sequential somatic mutations)
loss of tumor suppressor gene
associated with several loci on chromosomes 11p15 (wt2, ), 16 (wt3, ), 17 (wt4, ), and 7 (wt5, ).



Classifications:

Orphanet: 55  
Rare renal diseases


External Ids:

OMIM 53 194070
Disease Ontology 12 DOID:2154 DOID:5176
MeSH 41 D009396
Orphanet 55 ORPHA654
MESH via Orphanet 42 D009396
UMLS via Orphanet 70 C0027708
ICD10 via Orphanet 33 C64
MedGen 39 C0027708

Summaries for Wilms Tumor 1

NIH Rare Diseases : 49 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 654Disease definitionNephroblastoma is the most frequent malignant renal tumor in children and is associated with an abnormal proliferation of cells that resemble the kidney cells of an embryo (metanephroma), leading to the term embryonal tumor.EpidemiologyThe annual incidence is estimated at about 1/10,000 births and it affects boys as well as girls.Clinical descriptionNephroblastoma mainly affects young children, between the ages 1 and 5 years, but 15% of nephroblastomas occur before the age of 1 year and 2% after the age of 8 years. Adult forms are very rare. An abdominal mass (unilateral in most cases) is frequently present. Patients sometimes experience abdominal pain (around 10% of cases), hypertension, fever (20% of cases), hematuria and anemia. The evolution of the disease is very rapid, with regional dissemination in the retroperitoneal space, lymph nodes, vessels (renal vein and inferior vena cava) and in the peritoneal cavity in cases of tumor effraction, and a strong likelihood of metastases in the lungs and liver.EtiologyNephroblastoma is sporadic in 99% of cases and, among these cases, 10% are associated with congenital anomalies (aniridia, hemihypertrophy, genitourinary defects) or form part of specific syndromes (Beckwith-Wiedemann, Denys-Drash, WAGR or Perlman syndromes; see these terms). Genetic anomalies found in different chromosomal regions, including 11p13 (containing the WT1 gene), 11p15.5 (containing the H19 gene), 16q, 1p, 1q and 17p, have been found within the tumors. Familial forms are very rare (1% of cases) and are transmitted in an autosomal dominant fashion.Diagnostic methodsDiagnosis is based on imagery, particularly CT or MRI scans. The concentration of urinary metabolites of catecholamines is normal. Analysis of the extent of the disease is also conducted using imagery (ultrasound and abdominal CT analyzing particularly the liver and contralateral kidney, and thoracic radiography and CT).Differential diagnosisDifferential diagnoses include other renal tumors in children such as mesoblastic nephroma (especially in infants), clear cell sarcoma, neuroblastoma (extremely rare in the kidney but may invade the kidney by contiguity), rhabdoid tumors (see these terms) and metanephric stromal tumors.Management and treatmentDisease management is multidisciplinary and may involve chemotherapy and surgery with or without radiotherapy. Chemotherapy enables preoperative reduction in tumor size and eradicates metastases. Surgery should be accomplished without tumor effraction, which usually means that total nephrectomy is required. Nephroblastoma can be confirmed on microscopic examination, which also allows the stage of the tumor in the kidney to be evaluated. This in turn determines the choice of post-operative chemotherapy. Radiotherapy is reserved for the most extensive cases or cases with the least favorable histology.PrognosisIn the majority of cases, the prognosis is favorable with a survival rate of over 90%. Adult forms have the same prognosis and should be treated following the same methods, even when adult patients tolerate chemotherapy less well than children (which may lead to a reduction in treatment and as a result a worse prognosis).Visit the Orphanet disease page for more resources. Last updated: 3/10/2010

MalaCards based summary : Wilms Tumor 1, also known as nephroblastoma, is related to frasier syndrome and wilms tumor 6, and has symptoms including fever, abdominal pain and hypertension. An important gene associated with Wilms Tumor 1 is WT1 (Wilms Tumor 1), and among its related pathways/superpathways are HTLV-I infection and Proteoglycans in cancer. The drugs Itraconazole and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include kidney, myeloid and bone, and related phenotypes are cellular and cardiovascular system

OMIM : 53 Wilms tumor is the most common renal tumor of childhood, occurring with an incidence of 1 in 10,000 and with a median age of diagnosis between 3 and 4 years of age. Wilms tumours are thought to develop from abnormally persistent embryonal cells within nephrogenic rests. Histologically, Wilms tumor mirrors the development of the normal kidney and classically consists of 3 cell types: blastema, epithelia, and stroma (summary by Slade et al., 2010). (194070)

UniProtKB/Swiss-Prot : 71 Wilms tumor 1: Embryonal malignancy of the kidney that affects approximately 1 in 10'000 infants and young children. It occurs both in sporadic and hereditary forms.

Disease Ontology : 12 A kidney cancer that affects the kidneys and typically located in children.

Wikipedia : 72 Wilms tumor, also known as nephroblastoma, is a cancer of the kidneys that typically occurs in children,... more...

Related Diseases for Wilms Tumor 1

Diseases in the Hereditary Wilms' Tumor family:

Wilms Tumor 1 Wilms Tumor 2
Wilms Tumor 3 Wilms Tumor 4
Wilms Tumor 5 Wilms Tumor 6
Familial Wilms Tumor 2

Diseases related to Wilms Tumor 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 101)
# Related Disease Score Top Affiliating Genes
1 frasier syndrome 32.6 NPHS2 NR5A1 SRY WT1
2 wilms tumor 6 31.6 CTNNB1 REST
3 hereditary wilms' tumor 31.0 IGF2 REST WT1
4 denys-drash syndrome 30.7 NPHS2 NR5A1 WT1
5 wilms tumor 5 30.7 CTNNB1 GPC3 H19 IGF2 POU6F2 SYNPO
6 hypospadias 30.3 NR5A1 SRY WT1
7 wilms tumor 4 11.2
8 childhood multilocular cystic kidney neoplasm 11.1
9 mixed cell type kidney wilms' tumor 11.1
10 blastema predominant kidney wilms' tumor 11.1
11 epithelial predominant wilms' tumor 11.1
12 stromal predominant kidney wilms' tumor 11.1
13 cerebellar angioblastoma 10.8 TP53 WT1
14 46,xy partial gonadal dysgenesis 10.8 NR5A1 SRY WT1
15 female reproductive endometrioid cancer 10.8 CTNNB1 TP53 WT1
16 persistent mullerian duct syndrome 10.8 CTNNB1 NR5A1 SRY WT1
17 crescentic glomerulonephritis 10.7 NPHS2 SYNPO WT1
18 46 xy gonadal dysgenesis 10.7 NR5A1 SRY WT1
19 gonadal dysgenesis 10.7 NR5A1 SRY WT1
20 adult hepatocellular carcinoma 10.7 CTNNB1 TP53
21 cryptorchidism, unilateral or bilateral 10.6 NR5A1 SRY WT1
22 anorchia 10.6 NR5A1 SRY
23 embryonal sarcoma 10.6 CTNNB1 GPC3 TP53
24 malignant ovarian surface epithelial-stromal neoplasm 10.6 BRCA2 TP53 WT1
25 ovary epithelial cancer 10.6 BRCA2 TP53 WT1
26 ovarian cancer 1 10.6 BRCA2 CTNNB1 TP53 WT1
27 acinar cell carcinoma 10.6 BRCA2 CTNNB1 TP53
28 li-fraumeni syndrome 2 10.5 CHEK2 TP53
29 muscle cancer 10.5 IGF2 TP53 WT1
30 pancreas adenocarcinoma 10.5 BRCA2 CTNNB1 TP53
31 female reproductive organ cancer 10.5 BRCA2 CTNNB1 TP53
32 non-proliferative fibrocystic change of the breast 10.5 SRY TP53
33 intrahepatic cholangiocarcinoma 10.5 CTNNB1 GPC3 TP53
34 adrenocortical carcinoma, hereditary 10.5 IGF2 NR5A1 TP53
35 leukemia 10.5
36 reproductive organ cancer 10.5 BRCA2 CTNNB1 TP53
37 uterine corpus serous adenocarcinoma 10.4 BRCA2 TP53
38 46,xx sex reversal 1 10.4 NR5A1 SRY
39 tetraploidy 10.4 BRCA2 TP53
40 meninges sarcoma 10.4 IGF2 TP53
41 renal oncocytoma 10.4
42 hereditary breast ovarian cancer syndrome 10.4 BRCA2 CHEK2 TP53
43 silver-russell syndrome due to an imprinting defect of 11p15 10.4 H19 IGF2
44 sporadic breast cancer 10.4 BRCA2 CHEK2 TP53
45 silver-russell syndrome due to 11p15 microduplication 10.4 H19 IGF2
46 myeloid leukemia 10.4
47 hemihyperplasia, isolated 10.3 H19 IGF2 WT1
48 simpson-golabi-behmel syndrome, type 1 10.3 GPC3 GPC4
49 beckwith-wiedemann syndrome due to imprinting defect of 11p15 10.3 H19 IGF2
50 leiomyosarcoma 10.3 CHEK2 IGF2 TP53 WT1

Graphical network of the top 20 diseases related to Wilms Tumor 1:



Diseases related to Wilms Tumor 1

Symptoms & Phenotypes for Wilms Tumor 1

Symptoms via clinical synopsis from OMIM:

53
Genitourinary Kidneys:
nephroblastoma

Neoplasia:
nephroblastoma


Clinical features from OMIM:

194070

Human phenotypes related to Wilms Tumor 1:

55 31 (show all 11)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 55 31 occasional (7.5%) Occasional (29-5%) HP:0001945
2 abdominal pain 55 31 hallmark (90%) Very frequent (99-80%) HP:0002027
3 hypertension 55 31 occasional (7.5%) Occasional (29-5%) HP:0000822
4 weight loss 55 31 occasional (7.5%) Occasional (29-5%) HP:0001824
5 hematuria 55 31 occasional (7.5%) Occasional (29-5%) HP:0000790
6 neoplasm of the lung 55 31 occasional (7.5%) Occasional (29-5%) HP:0100526
7 lymphadenopathy 55 31 occasional (7.5%) Occasional (29-5%) HP:0002716
8 nephroblastoma 55 31 hallmark (90%) Very frequent (99-80%) HP:0002667
9 aniridia 55 31 occasional (7.5%) Occasional (29-5%) HP:0000526
10 neoplasm of the liver 55 31 occasional (7.5%) Occasional (29-5%) HP:0002896
11 neoplasm 55 Very frequent (99-80%)

UMLS symptoms related to Wilms Tumor 1:


abdominal pain

MGI Mouse Phenotypes related to Wilms Tumor 1:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.17 BRCA2 CHEK2 CTNNB1 EGR1 GPC3 IGF2
2 cardiovascular system MP:0005385 10.16 CTNNB1 EGR1 GPC3 IGF2 NPHS2 NR5A1
3 embryo MP:0005380 10.1 REST TP53 WT1 WTAP BRCA2 CTNNB1
4 hematopoietic system MP:0005397 10.06 REST TP53 TRIP13 WT1 BRCA2 CHEK2
5 endocrine/exocrine gland MP:0005379 10.02 CHEK2 CTNNB1 EGR1 IGF2 NR5A1 TP53
6 mortality/aging MP:0010768 9.97 BRCA2 CHEK2 CTNNB1 EGR1 GPC3 IGF2
7 limbs/digits/tail MP:0005371 9.86 BRCA2 CTNNB1 EGR1 GPC3 IGF2 REST
8 renal/urinary system MP:0005367 9.5 CTNNB1 GPC3 IGF2 NPHS2 SYNPO TP53
9 reproductive system MP:0005389 9.32 BRCA2 CTNNB1 EGR1 GPC3 IGF2 NR5A1

Drugs & Therapeutics for Wilms Tumor 1

Drugs for Wilms Tumor 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 271)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Itraconazole Approved, Investigational Phase 4,Phase 3 84625-61-6 55283
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
3 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
4 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2
5 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2
6 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
7 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
8 Hormones Phase 4,Phase 3,Phase 2,Phase 1
9 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
10 Hydroxyitraconazole Phase 4,Phase 3
11 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
12
Dactinomycin Approved, Investigational Phase 3,Phase 2 50-76-0 457193 2019
13
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
14
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
15
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
16
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
17
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
18
Azacitidine Approved, Investigational Phase 2, Phase 3,Phase 1 320-67-2 9444
19
Decitabine Approved, Investigational Phase 2, Phase 3,Phase 1 2353-33-5 451668
20
Cytarabine Approved, Investigational Phase 2, Phase 3, Phase 1 147-94-4 6253
21
Idarubicin Approved Phase 2, Phase 3 58957-92-9 42890
22
Daunorubicin Approved Phase 3,Phase 1,Phase 2 20830-81-3 30323
23
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
24
Sulfamethoxazole Approved Phase 3 723-46-6 5329
25
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
26
Fludarabine Approved Phase 2, Phase 3, Phase 1 21679-14-1, 75607-67-9 30751
27
Morphine Approved, Investigational Phase 3 57-27-2 5288826
28
Mycophenolate mofetil Approved, Investigational Phase 3 128794-94-5 5281078
29
Mycophenolic acid Approved Phase 3 24280-93-1 446541
30
Captopril Approved Phase 3 62571-86-2 44093
31
Palivizumab Approved, Investigational Phase 3 188039-54-5
32
Ribavirin Approved Phase 3 36791-04-5 37542
33
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
34
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
35
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
36
Histamine Approved, Investigational Phase 3,Phase 1,Phase 2 51-45-6, 75614-87-8 774
37
Cyproheptadine Approved Phase 3 129-03-3 2913
38
Glutamic Acid Approved, Nutraceutical Phase 3 56-86-0 33032
39
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
40 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Early Phase 1
41 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
42 Antimitotic Agents Phase 3,Phase 2,Phase 1
43 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
44 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
45 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
46 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Early Phase 1
47 Etoposide phosphate Phase 3,Phase 2,Phase 1
48 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
49 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
50 Antimetabolites Phase 2, Phase 3, Phase 1

Interventional clinical trials:

(show top 50) (show all 234)

# Name Status NCT ID Phase Drugs
1 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4 itraconazole
2 Collaborative Wilms Tumour Africa Project Recruiting NCT01991652 Phase 4
3 Chemotherapy Plus Surgery in Treating Children at Risk of or With Stage I Wilms' Tumor Unknown status NCT00003804 Phase 3 vincristine sulfate
4 Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor Unknown status NCT00047138 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
5 Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome Unknown status NCT01809392 Phase 2, Phase 3 decitabine
6 WT1 for the Detection of Minimal Residual Disease Completed NCT00179829 Phase 2, Phase 3
7 Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor Completed NCT00379340 Phase 3 doxorubicin hydrochloride;liposomal vincristine sulfate;cyclophosphamide;etoposide
8 Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor Completed NCT00352534 Phase 3 vincristine sulfate;doxorubicin hydrochloride
9 Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors Completed NCT00002610 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
10 Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer Completed NCT00002611 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
11 Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer Completed NCT00369564 Phase 3 glutamic acid
12 Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML) Completed NCT00909168 Phase 2, Phase 3 FLAIMy - Fluda, Ida, Ara-C, Mylotarg
13 Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk Completed NCT00860639 Phase 3 gemtuzumab ozogamycin
14 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
15 HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk Completed NCT02461121 Phase 3 cyclosporine A;Mycophenolate mofetil;Ara-C;fludarabine;anti-lymphocyte globulin;cyclophosphamide
16 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
17 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
18 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
19 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
20 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
21 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
22 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
23 A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old Completed NCT00927498 Phase 3 conventional chemotherapy (AraC + Daunorubicin),;Mylotarg associated with conventional chemotherapy (AraC + Daunorubicin),
24 Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor Active, not recruiting NCT00945009 Phase 3 Doxorubicin Hydrochloride;Vincristine Sulfate;Carboplatin;Cyclophosphamide;Etoposide Phosphate
25 Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer Active, not recruiting NCT01987596 Phase 3
26 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
27 Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia Unknown status NCT01513109 Phase 1, Phase 2
28 WT1 Peptid Vaccination in Carcinomas Unknown status NCT00153608 Phase 2
29 WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML) Unknown status NCT00153582 Phase 2
30 Chemotherapy Followed by Surgery and Radiation Therapy With or Without Stem Cell Transplant in Treating Patients With Relapsed or Refractory Wilms' Tumor or Clear Cell Sarcoma of the Kidney Unknown status NCT00025103 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;melphalan;vincristine sulfate
31 Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma Unknown status NCT00965224 Phase 2
32 Dendritic Cell Vaccination for Patients With Solid Tumors Unknown status NCT01291420 Phase 1, Phase 2
33 Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer Unknown status NCT02018458 Phase 1, Phase 2
34 Clinical Study of DC Plus CIK for Patients With Relapse Acute Leukemia After Allo-HSCT Unknown status NCT01956630 Phase 1, Phase 2
35 Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors Unknown status NCT00179816 Phase 1, Phase 2 High-Dose Chemotherapy with Tandem PBSC Rescue.
36 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
37 Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation Unknown status NCT00036712 Phase 2
38 Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy Completed NCT00433745 Phase 2 WT1 Peptide Vaccine
39 Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy Completed NCT01265433 Phase 2
40 A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor Completed NCT00187031 Phase 2 Topotecan, Filgrastim (G-CSF), Pegfilgrastim
41 Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood Completed NCT00923910 Phase 1, Phase 2 WT1 Peptide-Pulsed Dendritic Cells;Donor Lymphocytes;IL-4;KLH;WT1 Peptides;Endotoxin;Diphenhydramine;Acetaminophen
42 Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer Completed NCT01502410 Phase 2 sorafenib tosylate
43 Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers Completed NCT00488592 Phase 2 GM-CSF (Sargramostim)
44 A Phase II Trial of All-Trans-Retinoic Acid in Combination With Interferon-Alpha 2a in Children With Recurrent Neuroblastoma or Wilms' Tumor Completed NCT00001509 Phase 2 IFN-alpha with retinoic acid
45 Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy Completed NCT01819558 Phase 1, Phase 2
46 Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer Completed NCT00002466 Phase 2 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
47 Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation Completed NCT00052520 Phase 1, Phase 2
48 A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation Completed NCT00405327 Phase 2
49 Safety and Efficacy Study of T-Guard to Treat Steroid-resistant Acute GVHD Completed NCT02027805 Phase 1, Phase 2
50 Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors Completed NCT00335556 Phase 2 Doxorubicin Hydrochloride;Irinotecan Hydrochloride;Cyclophosphamide;Etoposide;Carboplatin;Vincristine Sulfate

Search NIH Clinical Center for Wilms Tumor 1

Cochrane evidence based reviews: wilms tumor

Genetic Tests for Wilms Tumor 1

Genetic tests related to Wilms Tumor 1:

# Genetic test Affiliating Genes
1 Wilms Tumor 1 28 BRCA2 GPC3 GPC4 H19 IGF2 WT1
2 Nephroblastoma 28

Anatomical Context for Wilms Tumor 1

MalaCards organs/tissues related to Wilms Tumor 1:

38
Kidney, Myeloid, Bone, Bone Marrow, T Cells, Lung, Liver

The Foundational Model of Anatomy Ontology organs/tissues related to Wilms Tumor 1:

18
Children

Publications for Wilms Tumor 1

Articles related to Wilms Tumor 1:

(show top 50) (show all 144)
# Title Authors Year
1
Quantification of Wilms' tumor 1 mRNA by digital polymerase chain reaction. ( 28994041 )
2018
2
Wilms' Tumor 1 Overexpression in Granulosa Cells Is Associated with Polycystic Ovaries in Polycystic Ovary Syndrome Patients. ( 29414825 )
2018
3
Sensitive detection of rare antigen-specific T cells directed against Wilms' tumor 1 by FluoroSpot assay. ( 28573960 )
2018
4
Immunoreactivity of Wilms tumor 1 (WT1) as an additional evidence supporting hemangiomatous rather than inflammatory origin in the etiopathogenesis of angiolymphoid hyperplasia with eosinophilia. ( 29445571 )
2018
5
Wilms Tumor 1 (WT1) mRNA Expression Level at Diagnosis Is a Significant Prognostic Marker in Elderly Patients with Myelodysplastic Syndrome. ( 27866185 )
2017
6
Development of oral cancer vaccine using recombinant Bifidobacterium displaying Wilms' tumor 1 protein. ( 28299466 )
2017
7
Quantitative assessment of Wilms tumor 1 expression by real-time quantitative polymerase chain reaction in patients with acute myeloblastic leukemia. ( 28567073 )
2017
8
Clinical Utility of Wilms' Tumor 1 Monitoring in Patients with Myeloid Malignancy and Prior Allogeneic Hematopoietic Stem Cell Transplantation. ( 28673850 )
2017
9
Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients. ( 28163010 )
2017
10
Wilms Tumor 1 gene expression levels improve risk stratification in AML patients. Results of a multicentre study within the Spanish Group for Molecular Biology in Haematology. ( 28369773 )
2017
11
Turning back the Wheel: Inducing Mesenchymal to Epithelial Transition via Wilms Tumor 1 Knockdown in Human Mesothelioma Cell Lines to Influence Proliferation, Invasiveness, and Chemotaxis. ( 28054314 )
2017
12
Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML. ( 28067876 )
2017
13
Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1. ( 29100432 )
2017
14
Significance of Wilms' tumor 1 antigen as a cancer vaccine for pancreatic cancer. ( 28950074 )
2017
15
Transcription factor Wilms' tumor 1 regulates developmental RNAs through 3' UTR interaction. ( 28289143 )
2017
16
Differential detection of cytoplasmic Wilms tumor 1 expression by immunohistochemistry, western blotting and mRNA quantification. ( 27922671 )
2017
17
Nucleotide Transition 390C-T in the Wilms' Tumor 1 Gene: A Risk Factor of Hypospadias? ( 28878596 )
2017
18
Molecular cloning of canine Wilms' tumor 1 for immunohistochemical analysis in canine tissues. ( 28603218 )
2017
19
Prevalence and Prognostic Impact of Wilms' Tumor 1 (WT1) Gene, Including SNP rs16754 in Cytogenetically Normal Acute Myeloblastic Leukemia (CN-AML): An Iranian Experience. ( 26725263 )
2016
20
Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemia. ( 27252512 )
2016
21
microRNA-361 targets Wilms' tumor 1 to inhibit the growth, migration and invasion of non-small-cell lung cancer cells. ( 27779659 )
2016
22
The Simultaneous Elevation of Oxidative Stress Markers and Wilms' Tumor 1 Gene during the Progression of Myelodysplastic Syndrome. ( 27980269 )
2016
23
Wilms tumor 1 peptide vaccination after hematopoietic stem cell transplant in leukemia patients. ( 28078270 )
2016
24
Prognostic significance of Wilms tumor 1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes. ( 27062571 )
2016
25
Wilms' tumor 1 protein expression in endometrial adenocarcinoma and endometrial intra-epithelial neoplasia. ( 27062662 )
2016
26
Wilms' tumor 1 (WT1)-targeted cancer vaccines to extend survival for patients with pancreatic cancer. ( 27993090 )
2016
27
A novel functional variant in Wilms' tumor 1 (WT1) is associated with idiopathic non-obstructive azoospermia. ( 27990711 )
2016
28
Wilms' tumor 1 (WT1) protein expression in human developing tissues. ( 25858532 )
2015
29
Diagnostic Value of Wilms Tumor 1 and CD44 in Langerhans Cell Sarcoma: Case Series of 4 Patients. ( 25837753 )
2015
30
Wilms tumor 1 (WT1) protein: Diagnostic utility in pediatric tumors. ( 25881478 )
2015
31
Optimal time-points for minimal residual disease monitoring change on the basis of the method used in patients with acute myeloid leukemia who underwent allogeneic stem cell transplantation: a comparison between multiparameter flow cytometry and Wilms' tumor 1 expression. ( 25498507 )
2015
32
Risk-Reducing Genetic Variant of Wilms Tumor 1 Gene rs16754 in Korean Patients With BCR-ABL1-Negative Myeloproliferative Neoplasm. ( 25932444 )
2015
33
Wilms' tumor 1 (re)activation in evidence for both epicardial progenitor and endothelial cells for cardiovascular regeneration. ( 25863145 )
2015
34
Prognostic importance of expression of the Wilms' tumor 1 gene in newly diagnosed acute promyelocytic leukemia. ( 25426668 )
2015
35
Wilms' tumor 1 (WT1) expression and prognosis in solid cancer patients: a systematic review and meta-analysis. ( 25748047 )
2015
36
Oncofetal expression of Wilms' tumor 1 (WT1) protein in human fetal, adult and neoplastic skeletal muscle tissues. ( 25800978 )
2015
37
Wilms Tumor 1 rs16754 predicts favorable clinical outcomes for acute myeloid leukemia patients in South Chinese population. ( 25841655 )
2015
38
Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response. ( 25772149 )
2015
39
Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma. ( 26252465 )
2015
40
A Novel Missense Mutation of Wilms' Tumor 1 Causes Autosomal Dominant FSGS. ( 25145932 )
2014
41
Frequent hypermethylation of a CTCF binding site influences Wilms tumor 1 expression in Wilms tumors. ( 24534946 )
2014
42
Wilms' tumor 1 enhances Cisplatin-resistance of advanced NSCLC. ( 25447528 )
2014
43
Wilms tumor 1 gene mutations in patients with cytogenetically normal acute myeloid leukemia. ( 25035671 )
2014
44
Role of the Wilms' tumor 1 gene in the aberrant biological behavior of leukemic cells and the related mechanisms. ( 25310451 )
2014
45
Correlation of Wilms' tumor 1 isoforms with HER2 and ER-I+ and its oncogenic role in breast cancer. ( 24596380 )
2014
46
Transcriptional Repression of Tumor Suppressor CDC73, Encoding an RNA Polymerase II Interactor, by Wilms Tumor 1 Protein (WT1) Promotes Cell Proliferation: IMPLICATION FOR CANCER THERAPEUTICS. ( 24257751 )
2014
47
Overexpression of Wilms tumor 1 gene as a negative prognostic indicator in acute myeloid leukemia. ( 24667279 )
2014
48
High levels of Wilms' tumor 1 (WT1) expression were associated with aggressive clinical features in ovarian cancer. ( 24778040 )
2014
49
Wilms' tumor 1 is involved in tumorigenicity of glioblastoma by regulating cell proliferation and apoptosis. ( 24403445 )
2014
50
Prognostic relevance of Wilms tumor 1 (WT1) gene Exon 7 mutations in-patient with cytogenetically normal acute myeloid leukemia. ( 25435718 )
2014

Variations for Wilms Tumor 1

UniProtKB/Swiss-Prot genetic disease variations for Wilms Tumor 1:

71
# Symbol AA change Variation ID SNP ID
1 WT1 p.Pro181Ser VAR_007739 rs2234584
2 WT1 p.Ser223Asn VAR_007740
3 WT1 p.Gly253Ala VAR_007741
4 WT1 p.Arg366Cys VAR_007745
5 WT1 p.Arg366His VAR_007746
6 WT1 p.His373Gln VAR_007747
7 WT1 p.Arg394Trp VAR_007750
8 WT1 p.Cys355Gly VAR_043799
9 WT1 p.Arg394Leu VAR_043807

ClinVar genetic disease variations for Wilms Tumor 1:

6 (show all 29)
# Gene Variation Type Significance SNP ID Assembly Location
1 BRCA2 NM_000059.3(BRCA2): c.658_659delGT (p.Val220Ilefs) deletion Pathogenic rs80359604 GRCh37 Chromosome 13, 32903606: 32903607
2 BRCA2 NM_000059.3(BRCA2): c.5645C> G (p.Ser1882Ter) single nucleotide variant Pathogenic rs80358785 GRCh37 Chromosome 13, 32914137: 32914137
3 GPC3 NM_004484.3(GPC3): c.361C> T (p.His121Tyr) single nucleotide variant Pathogenic rs122453119 GRCh37 Chromosome X, 132888180: 132888180
4 GPC3 NM_004484.3(GPC3): c.1705G> A (p.Ala569Thr) single nucleotide variant Pathogenic rs122453120 GRCh37 Chromosome X, 132670190: 132670190
5 CTNNB1 NM_001904.3(CTNNB1): c.133_135delTCT (p.Ser45del) deletion Pathogenic rs587776850 GRCh38 Chromosome 3, 41224645: 41224647
6 CTNNB1 NM_001904.3(CTNNB1): c.134C> T (p.Ser45Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913409 GRCh37 Chromosome 3, 41266137: 41266137
7 BRCA2 NM_000059.3(BRCA2): c.5682C> G (p.Tyr1894Ter) single nucleotide variant Pathogenic rs41293497 GRCh37 Chromosome 13, 32914174: 32914174
8 BRCA2 NM_000059.3(BRCA2): c.7480C> T (p.Arg2494Ter) single nucleotide variant Pathogenic rs80358972 GRCh37 Chromosome 13, 32930609: 32930609
9 BRCA2 NM_000059.3(BRCA2): c.9117G> A (p.Pro3039=) single nucleotide variant Pathogenic rs28897756 GRCh37 Chromosome 13, 32954050: 32954050
10 BRCA2 NM_000059.3(BRCA2): c.145G> T (p.Glu49Ter) single nucleotide variant Pathogenic rs80358435 GRCh37 Chromosome 13, 32893291: 32893291
11 BRCA2 NM_000059.3(BRCA2): c.5857G> T (p.Glu1953Ter) single nucleotide variant Pathogenic rs80358814 GRCh37 Chromosome 13, 32914349: 32914349
12 WT1 NM_001198551.1(WT1): c.242_258del17 (p.Asn81Ilefs) deletion Pathogenic rs587776573 GRCh38 Chromosome 11, 32417633: 32417649
13 WT1 NM_001198551.1(WT1): c.443delG (p.Gly148Valfs) deletion Pathogenic rs587776574 GRCh38 Chromosome 11, 32399967: 32399967
14 WT1 NM_024426.4(WT1): c.1384C> T (p.Arg462Trp) single nucleotide variant Pathogenic rs121907900 GRCh37 Chromosome 11, 32413566: 32413566
15 WT1 NM_024426.4(WT1): c.1372C> T (p.Arg458Ter) single nucleotide variant Pathogenic rs121907909 GRCh37 Chromosome 11, 32413578: 32413578
16 WT1 NM_024426.4(WT1): c.1288C> T (p.Arg430Ter) single nucleotide variant Pathogenic rs121907906 GRCh37 Chromosome 11, 32414263: 32414263
17 WT1 NM_024426.4(WT1): c.531C> A (p.Tyr177Ter) single nucleotide variant Pathogenic rs121907911 GRCh37 Chromosome 11, 32456361: 32456361
18 GPC3 NM_004484.3(GPC3): c.1574-?_*379+?del deletion Pathogenic
19 WT1 NM_001198551.1(WT1): c.161delC (p.Pro54Argfs) deletion Pathogenic rs1060501253 GRCh38 Chromosome 11, 32428031: 32428031
20 GPC3 NC_000023.10: g.(?_132795758)_(132888203_?)del deletion Pathogenic GRCh37 Chromosome X, 132795758: 132888203
21 WT1 NM_024426.4(WT1): c.576delG (p.Ala193Profs) deletion Pathogenic rs1131690795 GRCh38 Chromosome 11, 32434770: 32434770
22 DIS3L2 NM_152383.4(DIS3L2): c.2380_2381delCG (p.Arg794Hisfs) deletion Likely pathogenic GRCh38 Chromosome 2, 232334721: 232334722
23 WT1 NM_001198551.1(WT1): c.229_231delTAC (p.Tyr77del) deletion Pathogenic GRCh38 Chromosome 11, 32427961: 32427963
24 CHEK2 NM_007194.3(CHEK2): c.1100_1101delCT (p.Thr367Argfs) deletion Pathogenic GRCh38 Chromosome 22, 28695868: 28695869
25 WT1 NC_000011.10: g.(?_32396251)_(32417660_?)del deletion Pathogenic GRCh38 Chromosome 11, 32396251: 32417660
26 WT1 NM_024426.4(WT1): c.319delG (p.Asp107Thrfs) deletion Pathogenic GRCh38 Chromosome 11, 32435027: 32435027
27 WT1 NM_024426.4(WT1): c.667dup (p.Asp223Glyfs) duplication Pathogenic GRCh37 Chromosome 11, 32450145: 32450145
28 GPC3 NC_000023.11: g.(?_133753462)_(133754196_?)dup duplication Likely pathogenic GRCh37 Chromosome X, 132887489: 132888223
29 GPC3 NM_004484.3(GPC3): c.629_654del26insCTTGCA (p.Asn210Thrfs) indel Pathogenic GRCh37 Chromosome X, 132887887: 132887912

Cosmic variations for Wilms Tumor 1:

9 (show all 21)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM21397 WT1 kidney,NS,Wilms tumour,unilateral c.1168C>T p.R390* 27
2 COSM21398 WT1 kidney,NS,Wilms tumour,unilateral c.461T>C p.F154S 27
3 COSM21408 WT1 kidney,NS,Wilms tumour,unilateral c.1096C>T p.R366C 27
4 COSM21439 WT1 kidney,NS,Wilms tumour,unilateral c.797A>G p.N266S 27
5 COSM21403 WT1 kidney,NS,Wilms tumour,unilateral c.1013C>A p.S338Y 27
6 COSM21971 WT1 kidney,NS,Wilms tumour,unilateral c.1112A>G p.K371R 27
7 COSM21967 WT1 kidney,NS,Wilms tumour,unilateral c.1180C>G p.R394G 27
8 COSM21401 WT1 kidney,NS,Wilms tumour,unilateral c.1084C>T p.R362* 27
9 COSM21445 WT1 kidney,NS,Wilms tumour,unilateral c.602G>A p.G201D 27
10 COSM21417 WT1 kidney,NS,Wilms tumour,unilateral c.1180C>T p.R394W 27
11 COSM21441 WT1 kidney,NS,Wilms tumour,unilateral c.901C>T p.R301* 27
12 COSM44510 TP53 kidney,NS,Wilms tumour,unilateral c.717C>G p.N239K 27
13 COSM5667 CTNNB1 kidney,NS,Wilms tumour,unilateral c.134C>T p.S45F 27
14 COSM13168 CTNNB1 kidney,NS,Wilms tumour,unilateral c.104T>C p.I35T 27
15 COSM5663 CTNNB1 kidney,NS,Wilms tumour,unilateral c.133T>C p.S45P 27
16 COSM5678 CTNNB1 kidney,NS,Wilms tumour,unilateral c.107A>C p.H36P 27
17 COSM5689 CTNNB1 kidney,NS,Wilms tumour,unilateral c.134C>G p.S45C 27
18 COSM5664 CTNNB1 kidney,NS,Wilms tumour,unilateral c.121A>G p.T41A 27
19 COSM5692 CTNNB1 kidney,NS,Wilms tumour,unilateral c.134C>A p.S45Y 27
20 COSM250063 AMER1 kidney,NS,Wilms tumour,unilateral c.565C>T p.Q189* 27
21 COSM28715 AMER1 kidney,NS,Wilms tumour,unilateral c.85G>A p.A29T 27

Copy number variations for Wilms Tumor 1 from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 24429 1 180300000 185800000 Microamplification CACNA1E Nephroblastoma

Expression for Wilms Tumor 1

Search GEO for disease gene expression data for Wilms Tumor 1.

Pathways for Wilms Tumor 1

Pathways related to Wilms Tumor 1 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.08 CHEK2 CTNNB1 EGR1 TP53
2 11.87 CTNNB1 GPC3 IGF2 TP53
3 11.44 BRCA2 CHEK2 CTNNB1 TP53
4
Show member pathways
11.42 BRCA2 CHEK2 TP53
5 10.79 CTNNB1 NPHS2 SYNPO WT1
6 9.85 CHEK2 TP53

GO Terms for Wilms Tumor 1

Cellular components related to Wilms Tumor 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.65 BRCA2 CHEK2 CTNNB1 EGR1 NR5A1 REST
2 nucleus GO:0005634 9.47 BRCA2 CHEK2 CTNNB1 EGR1 GPC4 NR5A1

Biological processes related to Wilms Tumor 1 according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription by RNA polymerase II GO:0006357 9.97 CTNNB1 NR5A1 REST SRY WT1
2 negative regulation of cell proliferation GO:0008285 9.8 CTNNB1 DIS3L2 GPC3 REST TP53 WT1
3 kidney development GO:0001822 9.76 CTNNB1 GPC3 WT1
4 cellular response to drug GO:0035690 9.71 CHEK2 REST TP53
5 double-strand break repair GO:0006302 9.69 BRCA2 CHEK2 TRIP13
6 branching involved in ureteric bud morphogenesis GO:0001658 9.65 CTNNB1 GPC3 WT1
7 response to gamma radiation GO:0010332 9.61 BRCA2 CHEK2 TP53
8 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.58 BRCA2 CHEK2 TP53
9 replicative senescence GO:0090399 9.56 CHEK2 TP53
10 transcription by RNA polymerase II GO:0006366 9.56 CTNNB1 EGR1 NR5A1 POU6F2 REST TP53
11 cellular response to gamma radiation GO:0071480 9.54 CHEK2 EGR1 TP53
12 sex determination GO:0007530 9.52 NR5A1 WT1
13 negative regulation of female gonad development GO:2000195 9.46 NR5A1 WT1
14 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.43 BRCA2 CHEK2 TP53
15 positive regulation of male gonad development GO:2000020 9.33 NR5A1 SRY WT1
16 positive regulation of transcription, DNA-templated GO:0045893 9.28 BRCA2 CHEK2 CTNNB1 EGR1 NR5A1 REST
17 transcription, DNA-templated GO:0006351 10.22 CHEK2 CTNNB1 EGR1 NR5A1 POU6F2 REST
18 regulation of transcription, DNA-templated GO:0006355 10.19 CHEK2 CTNNB1 EGR1 IGF2 NR5A1 POU6F2
19 negative regulation of transcription by RNA polymerase II GO:0000122 10.02 CTNNB1 EGR1 IGF2 REST TP53 WT1

Molecular functions related to Wilms Tumor 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.97 BRCA2 CTNNB1 EGR1 NR5A1 POU6F2 REST
2 transcription regulatory region DNA binding GO:0044212 9.35 CTNNB1 EGR1 REST TP53 WT1
3 double-stranded methylated DNA binding GO:0010385 9.26 EGR1 WT1
4 DNA binding transcription factor activity GO:0003700 9.23 CTNNB1 EGR1 NR5A1 POU6F2 REST SRY
5 hemi-methylated DNA-binding GO:0044729 9.16 EGR1 WT1

Sources for Wilms Tumor 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....